Oppenheimer Analysts Boost Earnings Estimates for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Research analysts at Oppenheimer boosted their Q4 2019 EPS estimates for Alexion Pharmaceuticals in a research report issued on Wednesday, October 23rd. Oppenheimer analyst H. Singh now expects that the biopharmaceutical company will earn $2.19 per share for the quarter, up from their previous estimate of $2.16.

Other equities research analysts have also issued reports about the stock. Piper Jaffray Companies set a $180.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, September 6th. Leerink Swann set a $157.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Bank of America initiated coverage on shares of Alexion Pharmaceuticals in a report on Thursday, October 17th. They set a “buy” rating on the stock. Cowen reissued a “buy” rating and set a $165.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, October 16th. Finally, BMO Capital Markets initiated coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 12th. They set an “outperform” rating and a $149.00 target price on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $159.00.

ALXN opened at $106.56 on Monday. Alexion Pharmaceuticals has a fifty-two week low of $92.56 and a fifty-two week high of $141.86. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.56. The firm has a market capitalization of $23.47 billion, a price-to-earnings ratio of 15.03, a PEG ratio of 1.03 and a beta of 1.67. The company’s 50 day moving average price is $102.24 and its two-hundred day moving average price is $117.07.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The firm had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the previous year, the firm posted $2.02 EPS. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year.

Hedge funds and other institutional investors have recently modified their holdings of the company. We Are One Seven LLC lifted its position in shares of Alexion Pharmaceuticals by 5.7% during the 2nd quarter. We Are One Seven LLC now owns 1,586 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 86 shares during the period. Signaturefd LLC lifted its position in shares of Alexion Pharmaceuticals by 13.2% during the 2nd quarter. Signaturefd LLC now owns 822 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 96 shares during the period. Investors Research Corp lifted its position in shares of Alexion Pharmaceuticals by 52.0% during the 3rd quarter. Investors Research Corp now owns 304 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 104 shares during the period. Fort Washington Investment Advisors Inc. OH lifted its position in shares of Alexion Pharmaceuticals by 6.5% during the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,810 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 111 shares during the period. Finally, Verity Asset Management Inc. lifted its position in shares of Alexion Pharmaceuticals by 4.1% during the 2nd quarter. Verity Asset Management Inc. now owns 2,842 shares of the biopharmaceutical company’s stock valued at $372,000 after acquiring an additional 112 shares during the period. Hedge funds and other institutional investors own 93.26% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: Investing strategies using the yield curve

Earnings History and Estimates for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.